<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588428</url>
  </required_header>
  <id_info>
    <org_study_id>MERS-201</org_study_id>
    <nct_id>NCT04588428</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers</brief_title>
  <official_title>Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inovio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coalition for Epidemic Preparedness Innovations</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Inovio Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is&#xD;
      to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by&#xD;
      intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA™ 2000 device&#xD;
      in healthy adult volunteers for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)&#xD;
      infection. This study is divided into 2 parts: Part 1- dose finding stage and Part 2- dose&#xD;
      expansion stage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2021</start_date>
  <completion_date type="Anticipated">June 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Adverse Events in Part 1</measure>
    <time_frame>Part 1: baseline up to Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events in Part 1</measure>
    <time_frame>Part 1: baseline up to Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Injection Site Reactions in Part 1</measure>
    <time_frame>Part 1: baseline up to Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Injection Site Reactions in Part 1</measure>
    <time_frame>Part 1: baseline up to Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Adverse Events of Special Interest (AESIs) in Part 1</measure>
    <time_frame>Part 1: baseline up to Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events of Special Interest (AESIs) in Part 1</measure>
    <time_frame>Part 1: baseline up to Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of MERS-CoV Antigen Specific Binding Antibodies in Part 1</measure>
    <time_frame>Part 1: baseline up to Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage MERS-CoV Antigen Specific Neutralizing Antibodies in Part 1</measure>
    <time_frame>Part 1: baseline up to Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Antigen Specific Cellular Immune Response in Part 1</measure>
    <time_frame>Part 1: baseline up to Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Seroconverted Participants in Part 1</measure>
    <time_frame>Part 1: baseline up to Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Overall Immune Response in Part 1</measure>
    <time_frame>Part 1: baseline up to Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Adverse Events in Part 2</measure>
    <time_frame>Part 2: baseline up to Week 68</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events in Part 2</measure>
    <time_frame>Part 2: baseline up to Week 68</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Injection Site Reactions in Part 2</measure>
    <time_frame>Part 2: baseline up to Week 68</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Injection Site Reactions in Part 2</measure>
    <time_frame>Part 2: baseline up to Week 68</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Adverse Events of Special Interest (AESIs) in Part 2</measure>
    <time_frame>Part 2: baseline up to Week 68</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events of Special Interest (AESIs) in Part 2</measure>
    <time_frame>Part 2: baseline up to Week 68</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of MERS-CoV Antigen Specific Binding Antibodies in Part 2</measure>
    <time_frame>Part 2: baseline up to Week 68</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage MERS-CoV Antigen Specific Neutralizing Antibodies in Part 2</measure>
    <time_frame>Part 2: baseline up to Week 68</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Antigen Specific Cellular Immune Response in Part 2</measure>
    <time_frame>Part 2: baseline up to Week 68</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Seroconverted Participants in Part 2</measure>
    <time_frame>Part 2: baseline up to Week 68</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Overall Immune Response in Part 2</measure>
    <time_frame>Part 2: baseline up to Week 68</time_frame>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">542</enrollment>
  <condition>Middle East Respiratory Syndrome Coronavirus (MERS-CoV)</condition>
  <arm_group>
    <arm_group_label>Part 1: INO-4700 Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one ID injection of 0.6 milligram (mg) of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: INO-4700 Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one ID injection of 1.0 mg of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: INO-4700 Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one ID injection of 1.0 mg of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: INO-4700 Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two ID injections (in an acceptable location on two different limbs) of 0.5 mg each of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: INO-4700 Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two ID injections (in an acceptable location on two different limbs) of 1.0 mg each of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo Group F</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive one ID injection of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo Group G</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive one ID injection of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo Group H</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive two ID injections (in an acceptable location on two different limbs) of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo Group I</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive two ID injections (in an acceptable location on two different limbs) of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Parts 2A and 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ID injection of INO-4700 based on optimal dose and regimen selection in Part 1 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4 or Week 8 and a booster dose at Week 48 (only for Part 2B participants receiving a third dose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INO-4700</intervention_name>
    <description>INO-4700 will be administered ID.</description>
    <arm_group_label>Part 1: INO-4700 Group A</arm_group_label>
    <arm_group_label>Part 1: INO-4700 Group B</arm_group_label>
    <arm_group_label>Part 1: INO-4700 Group C</arm_group_label>
    <arm_group_label>Part 1: INO-4700 Group D</arm_group_label>
    <arm_group_label>Part 1: INO-4700 Group E</arm_group_label>
    <arm_group_label>Part 2: Parts 2A and 2B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile saline sodium citrate (SSC) buffer (SSC-0001) will be administered ID.</description>
    <arm_group_label>Part 1: Placebo Group F</arm_group_label>
    <arm_group_label>Part 1: Placebo Group G</arm_group_label>
    <arm_group_label>Part 1: Placebo Group H</arm_group_label>
    <arm_group_label>Part 1: Placebo Group I</arm_group_label>
    <other_name>SSC-0001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CELLECTRA™ 2000</intervention_name>
    <description>EP using the CELLECTRA™ 2000 device will be administered following ID drug administration</description>
    <arm_group_label>Part 1: INO-4700 Group A</arm_group_label>
    <arm_group_label>Part 1: INO-4700 Group B</arm_group_label>
    <arm_group_label>Part 1: INO-4700 Group C</arm_group_label>
    <arm_group_label>Part 1: INO-4700 Group D</arm_group_label>
    <arm_group_label>Part 1: INO-4700 Group E</arm_group_label>
    <arm_group_label>Part 1: Placebo Group F</arm_group_label>
    <arm_group_label>Part 1: Placebo Group G</arm_group_label>
    <arm_group_label>Part 1: Placebo Group H</arm_group_label>
    <arm_group_label>Part 1: Placebo Group I</arm_group_label>
    <arm_group_label>Part 2: Parts 2A and 2B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Judged to be healthy by the Investigator on the basis of medical history, physical&#xD;
             examination and vital signs performed at Screening;&#xD;
&#xD;
          -  Able and willing to comply with all study procedures;&#xD;
&#xD;
          -  Screening laboratory results within normal limits;&#xD;
&#xD;
          -  Negative tests for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody and Human&#xD;
             Immunodeficiency Virus (HIV) antibody;&#xD;
&#xD;
          -  Screening electrocardiogram (ECG) deemed by the Investigator as having no clinically&#xD;
             significant findings (e.g. Wolff-Parkinson-White syndrome);&#xD;
&#xD;
          -  Be post-menopausal or be surgically sterile or have a partner who is sterile or use&#xD;
             medically effective contraception with a failure rate of &lt; 1% per year when used&#xD;
             consistently and correctly from screening until 3 months following last dose.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant or father children within&#xD;
             the projected duration of the trial starting with the screening visit until 3 months&#xD;
             following last dose;&#xD;
&#xD;
          -  History of respiratory diseases such as asthma, chronic obstructive pulmonary disease&#xD;
             (COPD) or chronic bronchitis;&#xD;
&#xD;
          -  Currently participating in or has participated in a study with an investigational&#xD;
             product within 30 days preceding Day 0;&#xD;
&#xD;
          -  Previous receipt of any vaccine within 30 days preceding Day 0 or planning to receive&#xD;
             any vaccine during the timeframe restricted per the protocol;&#xD;
&#xD;
          -  Previous receipt of an investigational vaccine product for the prevention of MERS;&#xD;
&#xD;
          -  Prior exposure to MERS-CoV or camels;&#xD;
&#xD;
          -  Participants who participate in MERS-201 Part 1 cannot participate in MERS-201 Part 2;&#xD;
&#xD;
          -  Fewer than two acceptable sites available for ID injection and EP considering the&#xD;
             deltoid and anterolateral quadriceps muscles;&#xD;
&#xD;
          -  Prisoner or participants who are compulsorily detained (involuntary incarceration);&#xD;
&#xD;
          -  Current or anticipated concomitant immunosuppressive therapy (excluding inhaled,&#xD;
             topical skin and/or eye drop-containing corticosteroids) prior to dosing. Systemic&#xD;
             corticosteroids must be discontinued at least 3 months prior to first dose;&#xD;
&#xD;
          -  Reported active drug or alcohol or substance abuse or dependence.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonaventure Orizu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Inovio Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inovio Call Center</last_name>
    <phone>(267) 440-4237</phone>
    <email>clinical.trials@inovio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Center, Irbid Specialty Hospital (CRC/ISH)</name>
      <address>
        <city>Irbid</city>
        <zip>21110</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pharmaceutical Research Center / Jordan University of Science and Technology</name>
      <address>
        <city>Irbid</city>
        <zip>22110</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kenya Medical Research Institute (KEMRI)/Walter Reed Project (WRP)</name>
      <address>
        <city>Kericho</city>
        <zip>20200</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ahero Clincal Trials Unit</name>
      <address>
        <city>Kisumu</city>
        <zip>40100</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hammoud Hospital University Medical Center</name>
      <address>
        <city>Saida</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Jordan</country>
    <country>Kenya</country>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Coronavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.</ipd_time_frame>
    <ipd_access_criteria>Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

